84 notices found. Showing 1–50.
| Document № | Drug | Registration № | Level | Type | Source |
|---|---|---|---|---|---|
|
184/QD-QLD
2026-03-31
|
Aceclofenac STELLA 100mg
Decision No. 184/QD-QLD on the recall of Aceclofenac STELLA 100mg due to a level 2 violation (Reg. No.: VD-20124-13)
|
VD-20124-13 | Level 2 | Quality violation | |
|
152/QD-QLD
2026-03-24
|
Aclon
Decision No. 152/QD-QLD on the recall of Aclon due to a level 2 violation (Reg. No.: VD-18521-13)
|
VD-18521-13 | Level 2 | Quality violation | |
|
46/QD-QLD
2026-01-26
|
Diacerin 50
Decision No. 46/QD-QLD on the recall of Diacerin 50 due to a level 3 violation (Reg. No.: 893110447024)
|
893110447024 | Level 3 | Quality violation | |
|
735/QD-QLD
2025-12-10
|
Diclofen
Decision No. 735/QD-QLD on the recall of Diclofen due to a level 2 violation (Reg. No.: VD-25150-16)
|
VD-25150-16 | Level 2 | Quality violation | |
|
696/QD-QLD
2025-11-25
|
Padobaby
Decision No. 696/QD-QLD on the recall of Padobaby due to a level 3 violation (Reg. No.: 893100414024 (old Reg. No.: VD-32292-19))
|
893100414024 | Level 3 | Quality violation | |
|
554/QD-QLD
2025-10-14
|
Pyfaclor Kid granules for oral suspension
Decision No. 554/QD-QLD on the recall of Pyfaclor Kid granules for oral suspension, Reg. No.: VD-26427-17
|
VD-26427-17 | — | Other | |
|
475/QD-QLD
2025-09-29
|
Pyfaclor Kid
Decision No. 475/QD-QLD on the recall of Pyfaclor Kid due to a level 2 violation (Reg. No.: VD-26427-17)
|
VD-26427-17 | Level 2 | Quality violation | |
|
358/QD-QLD
2025-07-17
|
Femancia
Decision No. 358/QD-QLD on the recall of Femancia, Reg. No.: VD-27929-17
|
VD-27929-17 | — | Other | |
|
1778/QLD-CL
2025-06-22
|
Alfachim 4.2 tablets
Official Letter No. 1778/QLD-CL on the notification of the recall of a drug with a level 2 violation (Alfachim 4.2 tablets (Chymotrypsin (equivalent to 21 microkatal chymotrypsin) 4200 IU), Reg. No.: VD-34573-20, Batch no.: 03010624; Mfg. date: 01/06/2024; Exp.: 01/06/2026)
|
VD-34573-20 | Level 2 | Quality violation | |
|
1513/QLD-CL
2025-06-04
|
Eye drops
Official Letter No. 1513/QLD-CL on the notification of the recall of a drug with a level 3 violation (Ofleye Drops eye and ear drops solution (Ofloxacin 0.3%), Reg. No.: 893115586524 (old Reg. No.: VD-32740-19), Batch no.: 011024; Mfg. date: 25/10/2024; Exp.: 24/10/2027)
|
893115586524 | Level 3 | Quality violation | |
|
1245/QLD-CL
2025-04-29
|
Tegrucil-1 tablets
Official Letter No. 1245/QLD-CL on the notification of the recall of a drug with a level 3 violation (Tegrucil-1 tablets (Acenocoumarol 1mg), Reg. No.: VD-27453-17, Batch no.: 241600, Mfg. date: 01/07/2024, Exp.: 01/07/2027)
|
VD-27453-17 | Level 3 | Quality violation | |
|
841/QLD-CL
2025-03-19
|
Pyfaclor Kid granules for oral suspension
Official Letter No. 841/QLD-CL on the notification of the recall of a drug with a level 3 violation (Pyfaclor Kid granules for oral suspension (Cefaclor 125mg), Reg. No.: VD-26427-17, Batch no.: 330823, Mfg. date: 10823, Exp.: 210826; Batch no.: 050124, Mfg. date: 250124, Exp.: 250127)
|
VD-26427-17 | Level 3 | Quality violation | |
|
712/QLD-CL
2025-03-05
|
Femancia hard capsules
Official Letter No. 712/QLD-CL on the notification of the recall of a drug with a level 2 violation (Femancia hard capsules (Elemental iron (as ferrous fumarate 305 mg) 100 mg; Folic acid 350 mcg), Reg. No.: VD-27929-17)
|
VD-27929-17 | Level 2 | Quality violation | |
|
685/QLD-CL
2025-02-28
|
Erythromycin 500mg film-coated tablets
Official Letter No. 685/QLD-CL on the notification of the recall of a drug with a level 2 violation (Erythromycin 500mg film-coated tablets (Erythromycin 500mg), Reg. No.: VD-31437-19, Batch no.: 022024, Mfg. date: 15/06/2024, Exp.: 15/06/2028)
|
VD-31437-19 | Level 2 | Quality violation | |
|
3716/QLD-CL
2024-11-13
|
Prednisolon 5mg tablets
Official Letter No. 3716/QLD-CL on the notification of the recall of a drug with a level 3 violation (Prednisolon 5mg tablets (Prednisolon 5mg), Reg. No.: VD-27065-17, Batch no.: 020523, Mfg. date: 10/05/23, Exp.: 10/05/26, manufactured by Tipharco Pharmaceutical JSC)
|
VD-27065-17 | Level 3 | Quality violation | |
|
3114/QLD-CL
2024-09-17
|
Reinal-5 hard capsules
Official Letter No. 3114/QLD-CL on the notification of the recall of a drug with a level 2 violation (Reinal-5 hard capsules (Flunarizin 5mg), Reg. No.: VD-30346-18, Batch no.: 240256; Mfg. date: 20/02/2024; Exp.: 20/02/2027, manufactured by Dat Vi Phu Pharmaceutical JSC)
|
VD-30346-18 | Level 2 | Quality violation | |
|
3105/QLD-CL
2024-09-16
|
Compacin powder for oral suspension
Official Letter No. 3105/QLD-CL on the notification of the recall of a drug with a level 2 violation (Compacin powder for oral suspension (Ciprofloxacin 250mg), Reg. No.: VD-29775-18, Batch no.: 011123, Mfg. date: 02/11/23, Exp.: 02/11/26, manufactured by Medisun Pharmaceutical JSC)
|
VD-29775-18 | Level 2 | Quality violation | |
|
3007/QLD-CL
2024-09-09
|
Cetecocenzitax tablets
Official Letter No. 3007/QLD-CL on the notification of the recall of a drug with a level 3 violation (Cetecocenzitax tablets (Cinarizin 25mg), Reg. No.: VD-20384-13, Batch no.: 01/0823, Mfg. date: 030823, Exp.: 030826, manufactured by Central Pharmaceutical JSC No. 3)
|
VD-20384-13 | Level 3 | Quality violation | |
|
3005/QLD-CL
2024-09-09
|
Zovitit capsules containing microgranules
Official Letter No. 3005/QLD-CL on the notification of the recall of a drug with a level 2 violation (Zovitit capsules containing microgranules (Acyclovir 200mg), Reg. No.: VN-15819-12, Batch no.: 0017, Mfg. date: 03/05/23, Exp.: 02/05/26, manufactured by S.C. Slavia Pharma S.R.L (Romania)
|
VN-15819-12 | Level 2 | Quality violation | |
|
2825/QLD-CL
2024-08-19
|
Cefaclor 375mg film-coated oblong tablets
Official Letter No. 2825/QLD-CL on the notification of the recall of a drug with a level 2 violation (Cefaclor 375mg film-coated oblong tablets (Cefaclor), Reg. No.: VD-14047-11, Batch no.: 0124, Mfg. date: 23/01/24, Exp.: 23/01/27, manufactured by the branch of Medical Pharmaceutical and Biological JSC)
|
VD-14047-11 | Level 2 | Quality violation | |
|
1310/QLD-CL
2024-05-09
|
Temozolomid Ribosepharm 100 mg
Official Letter No. 1310/QLD-CL on the notification of the recall of a drug with a level 3 violation (Temozolomid Ribosepharm 100 mg, Reg. No. VN2-626-17, Batch no.: 2J6001, Mfg. date: 17/8/2022, Exp.: 31/8/2025)
|
VN2-626-17 | Level 3 | Quality violation | |
|
627/QLD-CL
2024-02-28
|
Xylometazolin 0.05% nasal drops solution
Official Letter No. 627/QLD-CL on the notification of the recall of a drug with a level 2 violation (Xylometazolin 0.05% nasal drops solution, Reg. No.: VD-18682-13, Batch no.: 030523, Mfg. date: 19/05/2023, Exp.: 19/05/2025)
|
VD-18682-13 | Level 2 | Quality violation | |
|
598/QLD-CL
2024-02-26
|
Fluconazole hard capsules
Official Letter No. 598/QLD-CL on the notification of the recall of a drug with a level 3 violation (Fluconazole hard capsules (Fluconazole 150mg), Reg. No.: VN-16474-13, Batch no.: KE22638; Mfg. date: 10/10/2022; Exp.: 09/10/2025)
|
VN-16474-13 | Level 3 | Quality violation | |
|
384/QLD-CL
2024-02-06
|
Cetirizin film-coated tablets
Official Letter No. 384/QLD-CL on the notification of the recall of a drug with a level 3 violation (Cetirizin film-coated tablets (Cetirizin hydroclorid 10mg), Reg. No.: VD-20648-14, Batch no.: 21002B, Mfg. date: 250521, Exp.: 250524; Batch no.: 21001B, Mfg. date: 140421, Exp.: 140424)
|
VD-20648-14 | Level 3 | Quality violation | |
|
9358/QLD-CL
2023-09-08
|
PymeRoxitil film-coated tablets
Official Letter No. 9358/QLD-CL on the notification of the recall of a drug with a level 2 violation (PymeRoxitil film-coated tablets (Roxithromycin 150mg), Reg. No.: VD-28304-17, Batch no.: 010522, Mfg. date: 18/05/2022, Exp.: 18/05/2025)
|
VD-28304-17 | Level 2 | Quality violation | |
|
9058/QLD-CL
2023-08-21
|
H-inzole hard capsules
Official Letter No. 9058/QLD-CL on the notification of the recall of a drug with a level 3 violation (H-inzole hard capsules, Reg. No.: VN-18555-14, Batch no.: HT4-51, Mfg. date: 18/10/2022, Exp.: 17/10/2024)
|
VN-18555-14 | Level 3 | Quality violation | |
|
8895/QLD-CL
2023-08-10
|
Paineuron 15 tablets
Official Letter No. 8895/QLD-CL on the notification of the recall of a drug with a level 3 violation (Paineuron 15 tablets (Meloxicam 15mg), Reg. No.: VD-32650-19, Batch no.: 83034, Mfg. date: 29/01/2023, Exp.: 28/01/2026)
|
VD-32650-19 | Level 3 | Quality violation | |
|
5834/QLD-CL
2023-06-01
|
Duo Hexin Tab
Official Letter No. 5834/QLD-CL on the notification of the recall of Duo Hexin Tab due to a level 2 violation
|
— | Level 2 | Quality violation | |
|
2205/QLD-CL
2023-03-10
|
Locobile-200 hard capsules
Official Letter No. 2205/QLD-CL on the notification of the recall of a drug with a level 3 violation (Locobile-200 hard capsules (Celecoxib 200mg), Reg. No.: VN-21822-19, Batch no.: WLD21003E, Mfg. date: 04/02/2021, Exp.: 03/02/2024)
|
VN-21822-19 | Level 3 | Quality violation | |
|
1223/QLD-CL
2023-02-10
|
Tobradico
Official Letter No. 1223/QLD-CL on the notification of the recall of Tobradico ((Tobramycin (as Tobramycin sulfat) 15mg/5ml), Reg. No.: VD-19202-13, Batch no.: 0031022, Mfg. date: 02/10/2022, Exp.: 02/10/2024)
|
VD-19202-13 | — | Other | |
|
424/QLD-CL
2023-01-16
|
Myomethol
Official Letter No. 424/QLD-CL on the notification of the recall of substandard Myomethol
|
— | — | Quality violation | |
|
13598/QLD-CL
2022-12-26
|
Rabesta 20 gastro-resistant tablets
Official Letter No. 13598/QLD-CL on the notification of the recall of a drug with a level 2 violation (Rabesta 20 gastro-resistant tablets (Rabeprazol sodium 20mg))
|
— | Level 2 | Quality violation | |
|
13223/QLD-CL
2022-12-14
|
Levosum
Official Letter No. 13223/QLD-CL on the notification of the recall of Levosum
|
— | — | Other | |
|
13021/QLD-CL
2022-12-07
|
Npluvico
Official Letter No. 13021/QLD-CL on the notification of the recall of Npluvico due to a level 2 violation
|
— | Level 2 | Quality violation | |
|
12290/QLD-CL
2022-11-18
|
Greaxim 2g powder for injection
Official Letter No. 12290/QLD-CL on the notification of the recall of Greaxim 2g powder for injection, VD-33386-19 and Greaxim powder for injection, VD-18235-13
|
— | — | Other | |
|
10275/QLD-CL
2022-10-13
|
Batiwell
Official Letter No. 10275/QLD-CL on the recall of Batiwell, batch no. 00121
|
— | — | Other | |
|
9586/QLD-CL
2022-09-29
|
Batiwell oral solution
Official Letter No. 9586/QLD-CL on the recall of a substandard drug (Batiwell oral solution (Bromhexin hydroclorid 0.8mg/ml), Reg. No.: VD-31011-18, Control no.: 00121, Mfg. date: 08/03/2021, Exp.: 08/03/2024)
|
VD-31011-18 | — | Quality violation | |
|
9343/QLD-CL
2022-09-22
|
Official Letter No. 9343/QLD-CL on the notification of a drug recall
|
— | — | Other | |
|
6298/QLD-CL
2022-07-14
|
Capetero 500 film-coated tablets
Official Letter No. 6298/QLD-CL on the notification of the recall of a drug with a level 2 violation (Capetero 500 film-coated tablets (Capecitabine 500mg))
|
— | Level 2 | Quality violation | |
|
6125/QLD-CL
2022-07-13
|
Nutrohadi F oral syrup
Official Letter No. 6125/QLD-CL on the notification of the recall of a drug with a level 2 violation (Nutrohadi F oral syrup, Reg. No.: VD- 18684-13, Batch no.: 030221; Mfg. date: 240221; Exp.: 230224)
|
— | Level 2 | Quality violation | |
|
5667/QLD-CL
2022-06-30
|
Neometin tablets
Official Letter No. 5667/QLD-CL on the notification of the recall of a drug with a level 2 violation (Neometin tablets (Metronidazol 500mg; Neomycin sulphat 108.3mg; Nystatin 22.73mg))
|
— | Level 2 | Quality violation | |
|
3534/QLD-CL
2022-05-09
|
Zinnat Suspension 125mg granules for oral suspension
Official Letter No. 3534/QLD-CL on the notification of the recall of a drug with a level 2 violation (Zinnat Suspension 125mg granules for oral suspension (Cefuroxim axetil 125mg))
|
— | Level 2 | Quality violation | |
|
3447/QLD-CL
2022-05-04
|
Neurobion sugar-coated tablets
Official Letter No. 3447/QLD-CL on the notification of the recall of a drug with a level 3 violation (Neurobion sugar-coated tablets (Pyridoxin HCl (vitamin B6) 200mg; Vitamin B1 (Thiamin mononitrat) 100mg; Vitamin B12 (Cyanocobalamin) 200mcg))
|
— | Level 3 | Quality violation | |
|
2984/QLD-CL
2022-04-19
|
Navacarzol tablets
Official Letter No. 2984/QLD-CL on the notification of the recall of a drug with a level 2 violation (Navacarzol tablets (Carbimazole 5mg))
|
— | Level 2 | Quality violation | |
|
14458/QLD-CL
2021-12-08
|
Methotrexat Bidiphar 50mg/2ml
Official Letter No. 14458/QLD-CL on the recall of a batch of Methotrexat Bidiphar 50mg/2ml failing to meet quality standards
|
— | — | Quality violation | |
|
12887/QLD-CL
2021-10-21
|
NOVOTEC - 70 tablets
Official Letter No. 12887/QLD-CL on the notification of the recall of a drug with a level 2 violation (NOVOTEC - 70 tablets)
|
— | Level 2 | Quality violation | |
|
9764/QLD-CL
2021-08-20
|
Hoat Huyet Duong Nao sugar-coated tablets
Official Letter No. 9764/QLD-CL on the notification of the recall of a drug with a level 2 violation (Hoat Huyet Duong Nao sugar-coated tablets)
|
— | Level 2 | Quality violation | |
|
9171/QLD-CL
2021-08-06
|
Vitamin C 300mg film-coated tablets
Official Letter No. 9171/QLD-CL on the notification of the recall of a drug with a level 3 violation (Vitamin C 300mg film-coated tablets)
|
— | Level 3 | Quality violation | |
|
9155/QLD-CL
2021-08-05
|
Sucrate gel oral suspension
Official Letter No. 9155/QLD-CL on the notification of the recall of a drug with a level 3 violation (Sucrate gel oral suspension (Sucralfate 1g/5ml))
|
— | Level 3 | Quality violation | |
|
8968/QLD-CL
2021-07-30
|
Amoxicillin 500mg
Official Letter No. 8968/QLD-CL on the handling of substandard Amoxicillin 500mg
|
— | — | Quality violation |
Reference data. Decision number, drug name, registration number and violation level are parsed automatically from each notice title, so some notices may leave these fields blank. Verify against the signed recall decision PDF before relying on it for legal purposes.